spacer
home > epc > autumn 2008 > be alternative
PUBLICATIONS
European Pharmaceutical Contractor

Be Alternative

In preclinical drug development, in vitro studies are establishing themselves in a more prominent position. Because of ethical considerations, an increasing number of in vivo tests have been replaced by in vitro experiments. These tests are recommended by organisations such as the Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM), and (draft) Test Guidelines are accepted or sent for consideration to the European Medicines Agency (EMEA), the US Food and Drug Administration (FDA) and the Organization of Economic Cooperation and Development (OECD), which are all part of the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human use (ICH).

The National Institutes of Health (NIH) and other federal agencies are committed to the welfare of research animals. These animals are protected by law, regulations and policies to ensure that companies are sued as rarely as possible and with special care taken in order to ensure animals’ comfort. Alternative test methods are those that accomplish one or more of the three ‘Rs’:

  • Reducing the number of animals used in testing through improved science and experimental design
  • Refining experimental procedures so that animals experience less pain and distress
  • Replacing animals with non-animal systems where possible

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
Natalie MGM Appels obtained her Masters degree in Biopharmaceutical Sciences from the University of Leiden in 1998. Her career as a research scientist began at the spin-off company ScreenTec BV currently known as Kiadis BV. She received her PhD from the Netherlands Cancer Institute. Since 2006, she has been employed by NOTOX BV as a Study Director in the In Vitro ADME section.

Ilona Verbaan-Giebelen obtained her Masters degree in Medical Biology from the Free University of Amsterdam in 1999. She has worked as a Research Technician at Organon NV and received her PhD from the Centre for Experimental and Molecular Medicine at the Academic Medical Centre in Amsterdam. She joined NOTOX BV in 2008 as Study Director, Genetic and In Vitro Toxicology.

spacer
Natalie MGM Appels
spacer
spacer
spacer
Ilona Verbaan-Giebelen
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Amcor partners with Moda to offer innovative packaging solutions

Amcor is pleased to announce its partnership with Moda vacuum packaging systems in North America and Latin America. By combining Amcor’s shrink bag and rollstock film for meat and cheese with Moda’s system, producers can gain operational efficiencies and drive total cost savings.
More info >>

White Papers

The Importance of ADCC in Assessing Clinically Relevant Differences

Sartorius Stedim BioOutsource Ltd

Biosimilars have caused a revolution in the development of biologic drugs. The model for biosimilars is a combination of speed to market and low cost; these are fundamental to any biosimilar development project. The biosimilars pathway to approval is not always without difficulty, biosimilars are still relatively new, and as each new applicant is reviewed we are learning more and more about these molecules.
More info >>

 
Industry Events

World Vaccine Congress Europe

18-21 October 2020, Barcelona, Spain

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement